: 131 – 138 . 55 Kindler HL Friberg G Stadler WM . Bevacizumab (B) plus gemcitabine (G) in patient (pts) with advanced pancreatic cancer (PC): Updated results of a multi-center phase II trial (Abstr) . In: Proceedings of the American Society
Search Results
F. Anthony Greco
cancer of unknown primary: from autopsy to microarray . Eur J Cancer 2007 ; 43 : 2026 – 2036 . 3. Hurwitz H Fehrenbacher L Novotny W . Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer . N Engl J
Mohamedtaki A. Tejani, Anna ter Veer, Dana Milne, Rebecca Ottesen, Tanios Bekaii-Saab, Al B. Benson III, Deborah Schrag, Stephen Shibata, John Skibber, Martin Weiser, Neal Wilkinson, and Steven J. Cohen
provided in Table 2 . The most common combination was a fluoropyrimidine plus oxaliplatin with or without bevacizumab (37% and 33%, respectively). The remaining patients either received fluoropyrimidine/irinotecan or single-agent fluoropyrimidine
Lirong Liu, Fangfang Hou, Yufeng Liu, Wenzhu Li, and Haibo Zhang
hypermetabolic nodules in left hilar suggestive of lung cancer with obstructive pneumonia and bone and right adrenal metastases. (B1–B3) CT after 2 cycles of carboplatin/pemetrexed with bevacizumab shows left lower lobe atelectasis aggravated with a large
Philip J. Saylor and M. Dror Michaelson
trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer . N Engl J Med 2003 ; 349 : 427 – 434 . 7 Yang JC Sherry RM Steinberg SM . Randomized study of high-dose and low-dose interleukin-2 in
Courtney P. Williams, Andres Azuero, Kelly M. Kenzik, Maria Pisu, Ryan D. Nipp, Smita Bhatia, and Gabrielle B. Rocque
categories based on the reason for discordance, including (1) therapy mismatched with hormone receptor (HR) or HER2 status, (2) HER2-targeted therapy without chemotherapy, (3) nonapproved bevacizumab use, (4) adjuvant regimens received in the metastatic
Aparna Parikh, Chloe Atreya, W. Michael Korn, and Alan P. Venook
with capecitabine and oxaliplatin plus bevacizumab after 2 months with significant functional decline. Next-generation sequencing (NGS) of the primary tumor identified HER2 amplification and we were able to obtain trastuzumab-DM1 for off-label use
Himani Aggarwal, Kristin M. Sheffield, Li Li, David Lenis, Rachael Sorg, and Rebecca Miksad
Background: PTL is a prognostic factor for mCRC. Recent data suggest PTL is also predictive of survival benefit with cetuximab (CET) and bevacizumab (BEV). This study evaluated the prognostic and predictive effect of PTL in patients with KRAS WT
Andrew D. Zelenetz
Although complex, biologic agents are key components of modern therapy in multiple disciplines, particularly oncology. However, despite the fact that biosimilars (eg, filgrastim‐sndz, bevacizumab‐awwb, trastuzumab‐dkst, rituximab-abbs) have been approved in the United States, many clinicians are poorly informed about their unique pathway for approval. At the NCCN 2019 Annual Congress: Hematologic Malignancies, Dr. Andrew D. Zelenetz, Memorial Sloan Kettering Cancer Center, outlined important issues regarding the use of biosimilars, including extrapolation, interchangeability, and naming.
Brian Vicuna and Al B. Benson III
The treatment of stage II colon cancer is a controversial issue that has persisted for the past decade. Clinicians must understand that accurate assessment of risk factors is the key to identifying patients who will benefit from treatment. Pathologic staging for colon cancer is based on the American Joint Committee on Cancer 6th edition staging system. In addition, distinct pathologic factors characterize a patient at high risk for stage II disease. More recent retrospective data suggest that molecular markers and gene expression microarrays may be valuable as prognostic and predictive tests. Unfortunately, previous research studies were not powered to properly assess efficacy in stage II disease. However, 2 recent clinical trials, National Surgical Adjuvant Breast and Bowel Project C-07 and MOSAIC, have provided more insight into defining the optimal treatment approach. With the development of the newer therapeutic agents, oxaliplatin and bevacizumab, ongoing trials such as Intergroup E5202 should help determine risk versus benefit of chemotherapy in the adjuvant treatment of stage II colon cancer.
